Compare AbbVie Inc (ABBV) vs YieldMax COIN Option Income Strategy ETF (CONY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs YieldMax COIN Option Income Strategy ETF — how do they compare? AbbVie Inc trades at $253.76 (market cap $449.91B), while YieldMax COIN Option Income Strategy ETF trades at $19.89. The key difference: AbbVie Inc pays a 2.72% dividend while YieldMax COIN Option Income Strategy ETF pays none, and AbbVie Inc is trading nearer its 52-week high, YieldMax COIN Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| ABBV | CONY | |
|---|---|---|
Market Cap | $449.91B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $261.07 | $103.20 |
52-Week Low | $184.85 | $18.43 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
CONY trades at $20.80, up 1.96% today, amid a bearish technical signal with resistance at $21-$22. The ETF's financial ratios are not disclosed, but it generates weekly dividends, with recent payouts ranging from $0.24 to $0.56. News highlights YieldMax's distribution announcements, though articles warn of underlying declines despite high yields.
The outlook is cautious due to bearish technicals and concerns over sustainability of high distributions. Risks include volatility from options strategies and potential capital erosion. Analyst sentiment is mixed, with no consensus ratings available, suggesting careful evaluation for income-focused investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About YieldMax COIN Option Income Strategy ETF
CONY is an actively managed ETF that seeks to generate weekly income by selling call options on Coinbase (COIN) stock. It aims to provide high yield while maintaining exposure to the price movements of the crypto exchange.
Read more on CONY →
